Latest news in cancer
Efficacy of CAR T Cell Therapy in B-Cell lymphoma Richter Transformation
CAR T cell therapy has shown promising efficacy in treating B-cell lymphoma Richter Transformation, a rare and aggressive disease. This advanced therapy...
Claudin18.2-targeted CAR-T cell therapy brings complete remission in advanced pancreatic cancer patient : A case report
Claudin18.2-targeted CAR-T cell therapy has shown remarkable potential in treating advanced pancreatic cancer, as highlighted in a recent case report. This...
What is the treatment after BCMA CAR T failed in R/R multiple myeloma cases?
For people with relapsed or refractory multiple myeloma, BCMA CAR T-cell therapy might not work. Other treatments, such as bispecific antibodies, other CAR...
CARSgen presents latest data of Satri-cel therapy in ASCO 2024
At ASCO 2024, CARSgen unveiled new data on Satri-cel, their promising CAR-T cell therapy for cancer treatment. The latest findings highlighted significant...
Can CAR T cell therapy shortcomings be avoided by NK Cell therapy?
NK Cell therapy vs CAR T-Cell therapy The FDA’s approval of the first CAR T cell therapy in 2017 was widely celebrated as a significant advancement in...
CAR T Cell therapy for refractory systemic lupus erythematosus in China
CAR T cell therapy has emerged as a promising treatment for refractory systemic lupus erythematosus (SLE) in China. This innovative approach involves...
Zevorcabtagene autoleucel (Zevra-cel therapy) approved for R/R multiple myeloma
SHANGHAI, China, April 30, 2024, CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the...
After amazing growth of CAR T-Cell therapy: what’s next?
CAR T-cell therapy has rapidly transformed cancer treatment by reprogramming a patient's T-cells to attack cancer cells, demonstrating remarkable success in...
Lutetium Lu 177 dotatate is approved by USFDA for pediatric patients 12 years and older with GEP-NETS
Lutetium Lu 177 dotatate, a groundbreaking treatment, has recently received approval from the US Food and Drug Administration (FDA) for pediatric patients,...
Nogapendekin alfa inbakicept-pmln is approved by the USFDA for BCG-unresponsive non-muscle invasive bladder cancer
"Nogapendekin Alfa Inbakicept-PMLN, a novel immunotherapy, shows promise in treating bladder cancer when combined with BCG therapy. This innovative approach...
Alectinib has been approved by the USFDA as adjuvant treatment for ALK-positive non-small cell lung cancer
The FDA's recent approval of alectinib marks a significant advancement in the treatment landscape for ALK-positive non-small cell lung cancer (NSCLC). As an...
NMPA approves zevorcabtagene autoleucel CAR T Cell therapy for R/R multiple myeloma
Zevor-Cel therapy Chinese regulators have approved zevorcabtagene autoleucel (zevor-cel; CT053), an autologous CAR T-cell therapy, for the treatment of adult...
Need help? Our team is ready to assist you.
We wish a speedy recovery of your dear and near one.